文献速递妇科

子宫内膜癌同源重组缺陷评分检测的临床意义

Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
PubMed 文献 · Gynecol Oncol · 2021-02-06

本研究在两个独立队列的253例子宫内膜样子宫内膜腺癌样本中检测HRD评分、MSI和TMB,发现HRD≥4与更差的无病生存趋势相关,且按分子亚型分组后组间生存差异显著;HRD评分高的Hec1a模型对奥拉帕利敏感。

要点

  • HRD≥4的子宫内膜癌患者无病生存趋势更差。
  • 按分子亚型分组后HRD≥4 cutoff组间生存差异显著。
  • HRD高评分Hec1a模型对奥拉帕利敏感。

核心结论

  • 高HRD评分与患者队列中更差的无病生存相关。
  • HRD评分可能在晚期或复发子宫内膜癌患者中具有临床效用。

研究设计与样本

  • 研究纳入两个独立队列共253例子宫内膜样子宫内膜腺癌样本,使用Myriad HRD assay检测HRD评分,使用二代测序检测MSI和TMB。
  • 同时在子宫内膜癌细胞系中生成HRD评分,并评估奥拉帕利的体内反应。

主要发现

  • 采用ROC曲线确定HRD与生存影响的最佳cutoff,基于发现队列建议HRD≥4作为DFS的cutoff。
  • 两个独立队列中HRD评分≥4的患者相比HRD评分<4者倾向于更差生存。
  • 按分子亚型分为四组(TMB阳性、MSI阳性、HRD阳性、其他)后,使用HRD≥4 cutoff在初始队列(p=0.0024)和复制队列(p=0.042)中组间差异显著。
  • Hec1a模型(HRD评分=19)在体外和体内实验中对奥拉帕利高度敏感。

关键数值与推荐

  • 基于发现队列的ROC曲线分析,建议HRD≥4作为DFS的cutoff。
  • 按分子亚型分组后,HRD≥4 cutoff在初始队列p=0.0024、复制队列p=0.042。

临床怎么用

  • HRD评分可能有助于识别晚期或复发子宫内膜癌中可能从PARP抑制剂治疗中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homologous recombination deficiency (HRD) score is related to chemotherapy response in some cancers, but its role in endometrial cancer in not known. We determined frequency and clinical significance of alterations in the HR pathway in endometrial cancer. METHODS: 253 endometrioid endometrial adenocarcinoma (EEA) samples from two independent cohorts (discovery and replication) were tested for HRD score using the Myriad HRD assay, microsatellite instability (MSI) and tumor mutation burden (TMB) using a next generation sequencing assay. HRD scores were also generated on endometrial cancer cell lines and in vivo response to olaparib was assessed. RESULTS: ROC curves were employed to determine optimal cutoffs of HRD in relation to survival impact in endometrial cancer and a cutoff of HRD ≥ 4 was suggested for DFS using the discovery cohort. Patients from two independent cohorts with HRD score ≥ 4 trended toward worse survival as compared to those with HRD score < 4. Both cohorts were further separated into four groups according to molecular subtypes (TMB positive; MSI positive; HRD positive; all others). When grouped by molecular subtype, there was a significant difference between groups using an HRD ≥4 cutoff in the initial (p = 0.0024) and replication (p = 0.042) cohorts. The Hec1a model (HRD score = 19) was highly sensitive to olaparib in in vitro and in vivo experiments. CONCLUSIONS: High HRD score was associated with worse DFS in our patient cohort. These findings suggest that HRD score may have clinical utility in patients with advanced or recurrent endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Siedel JH, Ring KL, Hu W, et al. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021. PMID: 33563487. doi:10.1016/j.ygyno.2020.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。